In response to the Form 483 issued by the US FDA containing thirteen observations, the Company had submitted a detailed corrective and preventive action (CAP A) plan to the regulator within the stipulated timeline. The inspection has now been closed by the US FDA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content